Designing Decentralised Clinical Trials for Patient Diversity
Data shows that most DCT approaches significantly improve patient diversity. This analysis examines what the evidence means for clinical trial design strategy.
Decentralised clinical trials promise to transform drug development and pharma strategy. The evidence tells a complex story. Here is what’s working and what still needs to be fixed.
Select the Right Data Collection Method for Real-World Evidence
Choosing the wrong RWE data source undermines your regulatory strategy. This framework helps pharma leaders select the right real-world data collection method based on your programme’s research question.
Cell Therapy for Solid Tumours: Current Challenges and New Advances
Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.
Can Deep Learning Survive the Precision Medicine Paradox?
As precision medicine narrows patient cohorts to rare‑disease scales, deep learning models face a paradox of data scarcity and overfitting that threatens the future of clinical AI.
Precision logistics in clinical trials is transforming global study execution through real-time tracking, cold-chain management, and advanced operational visibility.
